Cervical Cancer Prevention Week takes place in the UK from 23rd to 29th January 2023.
There are over 3000 new cases of cervical cancer every year in the UK alone. The Human Papilloma Virus (HPV) in strains HPV 16 and HPV 18 are the cause of cervical cancer through sexual contact causing the growth of abnormal cells in the cervix. Survival rates vary depending on the stage of detection, with later stages reducing down to just 20% chance of survival in stage four. Fortunately, increases in early detection, thanks to cervical screenings have been vital to preventing the development of early-stage cancer. Despite this, common cancer treatments such as chemotherapy can result in long-term side effects including, early menopause, infertility, and vaginal bleeding. The development of new immunotherapy treatments for cervical cancer, such as immune checkpoint inhibitors, hold potential to provide more targeted treatment.
It is in this spirit that Frontiers in Immunology is launching this new article collection to coincide with this awareness day. This occasion not only offers an opportunity to acknowledge Cervical Cancer Prevention Week but also to consider the importance of immunotherapy to the future of cervical cancer outcomes. This Research Topic accepts Original Research, Systematic Review, Methods, Review, Mini-Review, and Perspective and aims to offer new insights within the cervical cancer field.
We welcome manuscripts focusing on, but not limited to, the following sub-topics:
• Innovative immunotherapy to target cervical cancer cells during treatment.
• Research of immunotherapy approach reduction of long-term side effects associated with cervical cancer treatments.
• Preventative uses of immunotherapy on HPV 16 and HPV 18 to prevent transmission before infection.
We also take this opportunity to thank the wider community for their continued efforts in allowing for accelerated scientific developments within the cervical cancer field, and most importantly, for working with us on our mission to make science open.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Cervical Cancer Prevention Week takes place in the UK from 23rd to 29th January 2023.
There are over 3000 new cases of cervical cancer every year in the UK alone. The Human Papilloma Virus (HPV) in strains HPV 16 and HPV 18 are the cause of cervical cancer through sexual contact causing the growth of abnormal cells in the cervix. Survival rates vary depending on the stage of detection, with later stages reducing down to just 20% chance of survival in stage four. Fortunately, increases in early detection, thanks to cervical screenings have been vital to preventing the development of early-stage cancer. Despite this, common cancer treatments such as chemotherapy can result in long-term side effects including, early menopause, infertility, and vaginal bleeding. The development of new immunotherapy treatments for cervical cancer, such as immune checkpoint inhibitors, hold potential to provide more targeted treatment.
It is in this spirit that Frontiers in Immunology is launching this new article collection to coincide with this awareness day. This occasion not only offers an opportunity to acknowledge Cervical Cancer Prevention Week but also to consider the importance of immunotherapy to the future of cervical cancer outcomes. This Research Topic accepts Original Research, Systematic Review, Methods, Review, Mini-Review, and Perspective and aims to offer new insights within the cervical cancer field.
We welcome manuscripts focusing on, but not limited to, the following sub-topics:
• Innovative immunotherapy to target cervical cancer cells during treatment.
• Research of immunotherapy approach reduction of long-term side effects associated with cervical cancer treatments.
• Preventative uses of immunotherapy on HPV 16 and HPV 18 to prevent transmission before infection.
We also take this opportunity to thank the wider community for their continued efforts in allowing for accelerated scientific developments within the cervical cancer field, and most importantly, for working with us on our mission to make science open.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.